×

Cempra to Present Solithromycin Data at ID Week 2015

CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making two poster presentations at Infectious Disease Week 2015, being held in San Diego from October 7-11, 2015.

Both presentations will take place during the Poster Abstract Session on October 9, 2015 between 12:30 p.m. and 2:00 p.m. PDT in the Poster Hall.

  • Characterization of Mycoplasma pneumoniae Infection and Outcomes in the SOLITAIRE-Oral, Global Phase 3 Clinical Trial for Solithromycin – Poster Number 893, presented by David Oldach, M.D., FIDSA. The abstract is available here.
  • Detection of Pneumococcal Pneumonia in a Phase 3 Trial Comparing Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community-acquired Bacterial Pneumonia in Adults – Poster Number 894, presented by Jorge Vidal, Ph.D. The abstract is available here.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin has also entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and also being tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

CONTACT: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com

Source:Cempra, Inc.